Richard Bernstein Advisors LLC Has $2.92 Million Stake in Cencora, Inc. $COR

Key Points

• Richard Bernstein Advisors cut its stake in Cencora by 56.9%, selling 12,308 shares and holding 9,338 shares worth about $2.92 million at quarter-end.
• Company insiders have been net sellers — including CEO Robert Mauch who sold 5,096 shares — with total insider sales of 15,220 shares valued at roughly $5.28 million, leaving insiders with about 0.38% ownership.
• Cencora reported quarterly EPS of $4.08 (beating by $0.04) on $85.93 billion in revenue, has a market cap of ~$70.4 billion, and carries a consensus analyst rating of “Moderate Buy” with a $399 price target.

Richard Bernstein Advisors LLC lessened its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 56.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,338 shares of the company's stock after selling 12,308 shares during the period. Richard Bernstein Advisors LLC's holdings in Cencora were worth $2,918,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of COR. Vestcor Inc increased its holdings in shares of Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company's stock valued at $1,624,000 after purchasing an additional 28 shares during the last quarter. Cornerstone Wealth Group LLC grew its holdings in Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company's stock valued at $745,000 after buying an additional 30 shares in the last quarter. Security Financial Services INC. grew its holdings in Cencora by 2.6% in the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company's stock valued at $414,000 after buying an additional 33 shares in the last quarter. Hemington Wealth Management increased its stake in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company's stock worth $102,000 after acquiring an additional 35 shares during the last quarter. Finally, Quadcap Wealth Management LLC raised its holdings in shares of Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company's stock worth $722,000 after acquiring an additional 36 shares during the period. Institutional investors own 97.52% of the company's stock.

Cencora Trading Up 0.9%

Shares of NYSE:COR opened at $361.80 on Tuesday. Cencora, Inc. has a 52 week low of $251.94 and a 52 week high of $377.54. The company's 50 day moving average is $354.60 and its two-hundred day moving average is $337.09. The company has a market cap of $70.38 billion, a PE ratio of 43.49, a P/E/G ratio of 1.67 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the previous year, the business earned $3.73 EPS. Cencora's revenue for the quarter was up 5.5% on a year-over-year basis. Equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora's payout ratio is currently 28.85%.

Analyst Ratings Changes

COR has been the subject of several analyst reports. Barclays increased their price objective on Cencora from $400.00 to $425.00 and gave the stock an "overweight" rating in a research report on Friday, February 13th. JPMorgan Chase & Co. upped their price target on Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Jefferies Financial Group upgraded Cencora from an "underperform" rating to a "buy" rating in a report on Thursday, January 22nd. Robert W. Baird set a $415.00 price objective on Cencora in a research report on Tuesday, January 13th. Finally, Weiss Ratings upgraded shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a report on Thursday, February 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of "Moderate Buy" and a consensus price target of $399.00.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm's stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares of the company's stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 15,220 shares of company stock worth $5,282,867. 0.38% of the stock is owned by insiders.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.